Geneva, May 4 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123159) titled 'CBM588 in the Perioperative Period of Radical Gastrectomy for Gastric Cancer: A Single-Center Randomized Controlled Trial' on April 22.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Condition:
Gastric cancer
Intervention:
Probiotic group:Patients in the probiotic group will orally receive CBM588 (Miyairi Clostridium butyricum live tablets) from 7 days before surgery to 7 days after surgery (with the dose withheld on the day of surgery), at a dosage of 40 mg (20 mg per tablet, i.e., 2 tablets) three times da...